<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532218</url>
  </required_header>
  <id_info>
    <org_study_id>ARI-3037MO-005</org_study_id>
    <nct_id>NCT02532218</nct_id>
  </id_info>
  <brief_title>Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia</brief_title>
  <acronym>REASCEND</acronym>
  <official_title>Randomized Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arisaph Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arisaph Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of ARI-3037MO compared to&#xD;
      placebo in reducing low-density lipoprotein cholesterol (LDL-C) levels in subjects with&#xD;
      dyslipidemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, multi-center, randomized, double-blinded, controlled clinical&#xD;
      trial. The study will compare two arms: ARI-3037MO 3 g BID vs. placebo.&#xD;
&#xD;
      Subjects who sign informed consent will be enrolled and will undergo all Visit 1 assessments.&#xD;
      Following evaluation of Visit 1 laboratory assays, eligible subjects will receive a phone&#xD;
      call (Visit 2) during which they will be instructed to begin the lifestyle modification and&#xD;
      enter a 4- to 6-week lead-in period (6-week wash-out period for subjects to wash out of&#xD;
      non-statin lipid-lowering therapy [subjects may remain on statins during this period], 4&#xD;
      weeks for subjects receiving statins only or not receiving any lipid-lowering therapy),&#xD;
      followed by a qualifying fasting LDL-C measurement at Visit 3. After the lead-in period, if&#xD;
      the LDL-C level at Visit 3 is not ≥ 100 mg/dL, an additional week will be allowed for another&#xD;
      qualifying measurement at a subsequent visit (Visit 3.1). If performed, the LDL-C level at&#xD;
      Visit 3.1 must be ≥ 100 mg/dL in order for the subject to continue participation in the&#xD;
      study. Qualifying subjects will be randomized in a 1:1 manner at Visit 4 to one of two arms&#xD;
      of the double-blind, 24-week efficacy and safety assessment phase. Randomization will be&#xD;
      stratified by background statin therapy status at Visit 1 (yes/no). Baseline lipid levels&#xD;
      will be defined as lipid levels at Visit 4. End-of-study lipid levels will be defined as the&#xD;
      lipid levels at Visit 7 (Week 24).&#xD;
&#xD;
      A final closeout and safety assessment visit will be held at 26 weeks post randomization&#xD;
      (Visit 8).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-c</measure>
    <time_frame>24 wks</time_frame>
    <description>change in LDL cholesterol level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HDL-c</measure>
    <time_frame>24 wks</time_frame>
    <description>Change in HDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TG</measure>
    <time_frame>24 wks</time_frame>
    <description>Change in triglyceride levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C</measure>
    <time_frame>24 wks</time_frame>
    <description>Change in hemoglobin A1C</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ARI-3037MO (niacin analog) 3g bid for 24 wks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo 3g bid for 24 wks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARI-3037MO</intervention_name>
    <description>Lipid lowering treatment Statins</description>
    <arm_group_label>Active</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years at screening.&#xD;
&#xD;
          2. Women of childbearing potential, must agree to use 2 medically accepted, effective&#xD;
             methods of birth control. Females who are postmenopausal must have been postmenopausal&#xD;
             for &gt; 1 year if they wish not to use contraceptives. If postmenopausal status is&#xD;
             questionable, the subject's follicle-stimulating hormone level must be elevated and&#xD;
             consistent with postmenopausal levels (i.e., &gt; 40 IU/L); otherwise these subjects must&#xD;
             agree to use contraceptives listed above.&#xD;
&#xD;
          3. Male subjects with sexual partners of childbearing potential must be surgically&#xD;
             sterile or using an acceptable method of contraception from the time of screening&#xD;
             through 12 weeks after last dose of study drug to prevent pregnancy in a partner.&#xD;
&#xD;
          4. Female subjects of childbearing potential (including females with questionable&#xD;
             postmenopausal status) must have a negative pregnancy test prior to dosing.&#xD;
&#xD;
          5. LDL-C level: ≥ 100 mg/dL.&#xD;
&#xD;
          6. Triglycerides (TG) ≤ 300 mg/dL.&#xD;
&#xD;
          7. High-density lipoprotein cholesterol (HDL-C) level &lt; 45 mg/dL in men and &lt; 50 mg/dL in&#xD;
             women.&#xD;
&#xD;
          8. Subject understands the trial requirements and the treatment procedures, is willing to&#xD;
             comply with all protocol-required follow-up evaluation and provides written informed&#xD;
             consent&#xD;
&#xD;
          9. Subjects will be managed according to current standard of care. Subjects taking statin&#xD;
             therapy will remain on their statin background therapy and must be on a stable dose,&#xD;
             defined as no changes in the dose of statin in the 3 months prior to screening, and&#xD;
             must be willing and able to remain on that dose for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects treated with any statin at its maximally approved dose will be excluded from&#xD;
             the study.&#xD;
&#xD;
          2. Body mass index (BMI) &gt; 45 kg/m2.&#xD;
&#xD;
          3. Weight change ≥ 3 kg during the lead-in period.&#xD;
&#xD;
          4. Uncontrolled diabetes, defined as glycosylated hemoglobin (HbA1C) &gt; 9.5%.&#xD;
&#xD;
          5. Contraindication to niacin treatment (prior flushing is not regarded as a&#xD;
             contraindication to niacin treatment).&#xD;
&#xD;
          6. History of stroke, myocardial infarction, life-threatening arrhythmia, or having had&#xD;
             coronary vascularization within 6 months before screening.&#xD;
&#xD;
          7. Thyroid-stimulating hormone ≥ 1.5 times the upper limit of normal (ULN).&#xD;
&#xD;
          8. Clinical evidence of hypothyroidism or thyroid hormonal therapy that has not been&#xD;
             stable for ≥ 6 weeks before screening.&#xD;
&#xD;
          9. Creatine kinase concentration ≥ 3 times the ULN.&#xD;
&#xD;
         10. Known, active liver disease, including but not limited to&#xD;
&#xD;
               1. Confirmed alanine aminotransferase (ALT), aspartate aminotransferase (AST),&#xD;
                  alkaline phosphatase ≥ 2 times the ULN, or bilirubin ≥ 1.5 times the ULN.&#xD;
&#xD;
               2. Hepatitis C (anti-hepatitis C virus immunoglobulin G +).&#xD;
&#xD;
               3. Hepatitis B (hepatitis B surface antigen +, anti-hepatitis B core antigen&#xD;
                  immunoglobulin M +).&#xD;
&#xD;
         11. Blood donation of ≥ 1 pint (0.5 L) within 30 days before screening or plasma donation&#xD;
             within 7 days before screening.&#xD;
&#xD;
         12. Known nephrotic syndrome or ≥ 3 g/day proteinuria.&#xD;
&#xD;
         13. Past organ transplant or on a waiting list for an organ transplant.&#xD;
&#xD;
         14. Subject is currently receiving chemotherapy; or has received chemotherapy within the&#xD;
             30 days prior to screening; or is scheduled to receive chemotherapy during the course&#xD;
             of the study.&#xD;
&#xD;
         15. Other serious medical illness (e.g., cancer, congestive heart failure) with estimated&#xD;
             life expectancy of less than 12 months.&#xD;
&#xD;
         16. Problems with substance abuse, which, in the opinion of the Investigator, might affect&#xD;
             study compliance.&#xD;
&#xD;
         17. Planned procedure that may cause non-compliance with the protocol or confound data&#xD;
             interpretation.&#xD;
&#xD;
         18. Participation in another investigational drug trial in the past 30 days or current&#xD;
             participation in a device trial that has not reached its primary endpoint.&#xD;
&#xD;
         19. Female subjects who are pregnant, breastfeeding, or planning to become pregnant during&#xD;
             the study or within 12 weeks after last dose of study drug.&#xD;
&#xD;
         20. Estimated glomerular filtration rate &lt; 60 mL/min/1.73 m2. -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catalina Reserch Institute, LLC</name>
      <address>
        <city>Chino</city>
        <state>California</state>
        <zip>91710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S&amp;W Clinical Reserch</name>
      <address>
        <city>Ft Lauderdale</city>
        <state>Florida</state>
        <zip>33306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonvile</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sestron Clinical Research 833 Campbell Hill Street Suite 230</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisville Metabolic and Atherosclerosis Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester clinical Research,Inc</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group Ltd</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Carl and Edyth Lindner Center for Reserch and education at the Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic and atherosclerosis Research center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVA reserch</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research group, Ltd</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Clinical Research-Lyndhurst</name>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>COR Clinical Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Clinical studies</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads - Norfolk</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research inc</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raninier Clinical Reserach</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>August 21, 2015</study_first_submitted>
  <study_first_submitted_qc>August 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2015</study_first_posted>
  <last_update_submitted>August 5, 2016</last_update_submitted>
  <last_update_submitted_qc>August 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

